Tscan Therapeutics is trading 5.13% up now at $0.79, with the move appearing primarily volatility-driven rather than tied to a confirmed fundamental catalyst.
- No new bullish company announcement was identified; shares are reversing part of the August 19 decline.
- Amgen’s termination of the collaboration remains the key recent company-specific development, eliminating potential future milestone and royalty payments.
- Broader biotech and major U.S. indexes are lower, so sector or market strength does not explain today’s gain.